Developing a targeted treatment for alcohol-related liver disease
A Precision Medicine for Alcohol-Associated Liver Disease
This study is looking at how to use a new treatment method to help people with alcohol-related liver disease by focusing on a specific gene that affects liver damage, with the goal of finding better ways to prevent or treat this serious condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Genetobe INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10932948 on NIH RePORTER |
What this research studies
This research aims to create a precision medicine approach using RNA interference (RNAi) to treat alcohol-associated liver disease (AALD). AALD is a serious health issue that leads to high mortality rates and is a common reason for liver transplants. The study focuses on identifying genetic factors, particularly a specific mutation in the PNPLA3 gene, that contribute to the severity of liver damage in affected individuals. By targeting this mutation, the researchers hope to develop effective therapies that can prevent or treat AALD more successfully than current options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol-associated liver disease, particularly those with the PNPLA3 148 I>M genetic variant.
Not a fit: Patients without alcohol-associated liver disease or those who do not carry the specific genetic mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from alcohol-associated liver disease.
How similar studies have performed: Previous research has shown promise in using genetic targeting approaches for other liver diseases, indicating potential success for this novel method.
Where this research is happening
Ann Arbor, United States
- Genetobe INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Liu, Wanqing — Genetobe INC.
- Study coordinator: Liu, Wanqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.